Survodutide Powder CAS 2805997-46-8

Survodutide Powder (CAS 2805997-46-8) is a high-purity, synthetic peptide compound supplied as a lyophilized white to off-white powder. It is designed for scientific research, analytical studies, and pharmaceutical development workflows, including peptide characterization, formulation research, and reference standard use.

As a next-generation dual-pathway peptide structure, Survodutide Powder has attracted growing interest from biotechnology companies, pharmaceutical R&D teams, and contract research organizations (CROs) worldwide. Its well-defined amino acid sequence, reproducible synthesis process, and strong batch-to-batch consistency make it suitable for demanding research environments that require reliable peptide materials.

The therapeutic power of Survodutide lies in its sophisticated dual-agonist design:
GLP-1 Receptor Activation: This pathway is well-established for promoting insulin secretion in a glucose-dependent manner, delaying gastric emptying, and enhancing satiety in the brain, leading to reduced caloric intake.

Glucagon (GCG) Receptor Activation: This is the differentiating factor. Glucagon receptor agonism increases energy expenditure by enhancing hepatic fat metabolism and thermogenesis. This creates a synergistic effect: while GLP-1 activity reduces energy input, glucagon activity increases energy output.

This dual action is supported by compelling clinical evidence. A Phase II trial demonstrated that after 46 weeks of treatment, subjects on the highest dose achieved body weight reductions of up to 19%. Notably, 40% of participants in the high-dose group achieved a weight loss of ≥20%, and the weight loss curve had not plateaued by the end of the study period, suggesting potential for even greater efficacy with extended treatment.

Our Survodutide Powder is synthesized and controlled under stringent quality standards to ensure consistency and reliability for your critical research applications.

Survodutide is a versatile tool for exploring new frontiers in metabolic disease:

Obesity Pharmacology: Investigate the superior efficacy profile of dual agonism compared to single GLP-1 agents in models of diet-induced obesity.

MASH/NASH Therapeutics: Explore its significant potential as a best-in-class treatment. A Phase II study showed 83% of adult MASH patients achieved statistically significant histological improvement with Survodutide, compared to placebo.

Mechanistic & Combination Studies: Unravel the precise contributions of GCG vs. GLP-1 receptor activation to overall metabolic benefits, or study potential synergies with other therapeutic agents.

Formulation Development: Support early-stage work on novel delivery systems (e.g., sustained-release formulations) for this promising peptide.

We specialize in providing high-grade Survodutide Powder (CAS 2805997-46-8) to support the global research community. Our product is offered in various packaging sizes, from milligram quantities for initial assay development to gram-scale for extended preclinical studies.

Intended Use Statement:
This product is supplied as a biochemical research tool. It is intended for laboratory research use only by qualified professionals. It is not for diagnostic or therapeutic use in humans or animals.

To meet the diverse needs of global buyers, Survodutide Powder is available in flexible packaging options, including:
Small-scale research quantities
Pilot-scale development batches
Bulk supply for long-term projects
Packaging is designed to protect product integrity during international shipping and long-distance transport.
Custom labeling, documentation formats, and packaging configurations are available for professional buyers.

Each shipment of Survodutide Powder (CAS 2805997-46-8) can be accompanied by:
Certificate of Analysis (COA)
HPLC chromatograms
Mass spectrometry data
Batch traceability records
Safety and handling documentation (upon request)
This documentation supports internal quality review, supplier audits, and project compliance requirements.

Hot Tags: survodutide powder cas 2805997-46-8, China survodutide powder cas 2805997-46-8 manufacturers, suppliers, factory, 2805997-46-8, 6233-83-6, cas 121062 08 6, Epithalon peptide, semaglutide raw powder, Semax peptide